CMPI vs DSEY

Checkmate Pharmaceuticals Inc.

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Diversey Holdings Ltd.

Diversey Holdings, Ltd., through its subsidiaries, provides infection prevention and cleaning solutions in Europe, North America, Latin America, the Asia Pacific, the Middle East, and Africa. It operates through two segments, Institutional, and Food and Beverage. The company manufactures, markets, and sells infection prevention and personal care products; floor and building care chemicals; kitchen and mechanical ware wash chemicals, and machines; dosing and dispensing equipment; and floor care machines to healthcare, education, food service, retail and grocery, hospitality, and building service contractor industries. It also provides a range of engineering, consulting, and training services related to productivity management, water and energy management, and risk management. In addition, the company offers chemical products; engineering and equipment solutions; training; and knowledge-based services, as well as water treatment services to brewing, beverage, dairy, processed foods, pharmaceutical, and agriculture industries. Diversey Holdings, Ltd. was founded in 1923 and is headquartered in Northampton, United Kingdom.